Systematic Review of Pharmacoeconomic Studies Published in Algeria, Morocco, and Tunisia

Speaker(s)

Mokhtar MA1, Messafeur MEA1, Mazari OI2, Mahi D2, Selka MA3, Achouri MY2
1University Of Sidi Bel Abbes, Sidi Bel Abbes, Sidi Bel Abbes, Algeria, 2University of Sidi Bel Abbes, Sidi Bel Abbes, 01, Algeria, 3Tlemcen University, Tlemcen, Tlemcen, Algeria

OBJECTIVES: In recent years, the interest in pharmacoeconomics as a tool for healthcare decision-making has significantly increased. However, the quality of referenced studies remains a major concern, potentially undermining the effectiveness of decisions based on these data. This study aims to identify pharmacoeconomic publications in Maghreb countries (Morocco, Algeria, Tunisia) and critically evaluate the quality of these reports according to established CHEERS standards.

METHODS: A systematic search was conducted in May 2021 across four pertinent databases: PubMed, ScienceDirect, Scopus, and ResearchGate. This search identified 36 models, of which 12 met the inclusion criteria. The quality of the articles was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

RESULTS: Of the 36 articles identified, 12 complete studies met the inclusion criteria. The quality of the reports varied considerably, with a mean score of 19.67 (SD = 1.79) out of 24 points. A downward trend in the number and quality of pharmacoeconomic publications was observed over the period from 2006 to 2020. According to CHEERS standards, the quality of reporting for elements such as "Title," "Introduction," "Method Comparators," "Effectiveness Measurement," and "Choice of Health Outcomes" was generally satisfactory, although less than 100% of the studies fully adhered to these standards. In contrast, significant deficiencies were noted in areas such as the "Discount Rate," "Method of Analysis," and "Assumptions," with fewer than 30% of articles meeting these criteria. Other elements fell between these extremes, with 50-75% of studies complying with the criteria.

CONCLUSIONS: The results of our study indicate that certain reporting standards in pharmacoeconomic studies require substantial improvement. Enhancing these aspects will improve the reliability and utility of pharmacoeconomic evaluations for healthcare decision-making in the Maghreb region.

Code

EE124

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Drugs, No Additional Disease & Conditions/Specialized Treatment Areas